The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
2-year recurrence-free survival (RFS) in patients with detectable vs no detectable ctDNA after surgery
Timeframe: 24 Months
Neoadjuvant Cohort Primary Outcome: Response Monitoring
Timeframe: 24 Months
Definitive Treatment Cohort Primary Outcome
Timeframe: 24 Months